Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study

ABSTRACT Backgroud The high cost of blinatumomab in full doses of full treatments has led to dose reduction and fewer treatment cycles for most patients in China. With current needs for cost‐efficiency and resource management in health care, we retrospectively evaluated the clinical effects of short...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer medicine (Malden, MA) Ročník 13; číslo 24; s. e70515 - n/a
Hlavní autoři: Yin, Jin, Cai, Xiaoya, Qian, Bingxin, Liu, Ying, Li, Dengju
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States John Wiley & Sons, Inc 01.12.2024
John Wiley and Sons Inc
Wiley
Témata:
Acute lymphoblastic leukemia
Adolescent
Adult
Aged
Antibodies, Bispecific - administration & dosage
Antibodies, Bispecific - therapeutic use
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
blinatumomab
Bone marrow
Brief Communication
B‐cell acute lymphoblastic leukemia
Chemotherapy
Child
Drug Administration Schedule
Female
Health care
Humans
Infusions, Intravenous
Leukemia
Lymphatic leukemia
Male
Middle Aged
Monoclonal antibodies
Neutropenia
Patients
Pediatrics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality
relapsed/refractory
Remission (Medicine)
Resource management
Retrospective Studies
Salvage Therapy - methods
short‐course
Targeted cancer therapy
Treatment Outcome
Young Adult
United States > US
short‐course
relapsed/refractory
blinatumomab
B‐cell acute lymphoblastic leukemia
ISSN:2045-7634, 2045-7634
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:ABSTRACT Backgroud The high cost of blinatumomab in full doses of full treatments has led to dose reduction and fewer treatment cycles for most patients in China. With current needs for cost‐efficiency and resource management in health care, we retrospectively evaluated the clinical effects of short‐course blinatumomab treatment for R/R Ph‐ B‐ALL at our center. Methods Blinatumomab was administered with 24‐h continuous intravenous infusion (9 μg/day for the first 3 days and 28 μg/day for 6–10 days). The clinical data of 30 R/R B‐ALL patients were collected and analyzed. Results A total of 25 patients (83.3%) including 13 (43.3%) with a high leukemic load (> 50%) achieved morphological CR. Twelve patients (40%) were MRD‐negative. The estimated 2‐year OS rate was 82.62%. The 2‐year PFS rate was 78.35%. The estimated 2‐year OS and PFS were significantly better in patients receiving further treatment. Conclusions Our findings provide novel insights into the optimization of blinatumomab therapy, proposing a viable treatment alternative that aligns with current needs for cost‐efficiency and resource management in health care.
Bibliografie:Funding
Research Fund of Tongji Hospital (2024TJCR022), Natural Scinence Foundation of Hubei Province (2024AFD422) and Beijing Xisike Clinical Oncology Study Foundation‌ (Y‐SYBLD2022MS‐0062). This work was supported by National Natural Science Foundation of China, 82270177.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Funding: Research Fund of Tongji Hospital (2024TJCR022), Natural Scinence Foundation of Hubei Province (2024AFD422) and Beijing Xisike Clinical Oncology Study Foundation‌ (Y‐SYBLD2022MS‐0062). This work was supported by National Natural Science Foundation of China, 82270177.
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.70515